MT5111
12 Apr 2022
Trial Summary
A Phase 1b open-label, multicentre dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumours
Acronym:
MT-5111
ACTRN/NCT /ethics:
NCT04029922
Scientific title:
Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)
Sponsor / Cooperative group:
Molecular Templates, Inc.
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-11-12 |
| Anticipated End Date | 2025-05-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Meena Okera |
| Recruitment Status | Recruiting |